hVIVO PLC (AIM:HVO) said it has published previously reported data from the first-in-human phase I clinical study using mosquito vaccine AGS-v PLUS in e=BioMedicine. a peer-reviewed, open-access biomedical journal that is part of The Lancet Discovery Science.
In a statement, Yamin 'Mo' Khan, hVIVO’s chief executive, commented: “The data demonstrated that AGS-v PLUS was well tolerated and generated a robust immune response in participants, with no serious adverse events.
“The next steps will be to determine if these findings translate into clinical efficacy against mosquito-borne diseases, which inflict a severe burden on public health systems around the world."
AGS-v PLUS is a vaccine against arboviral diseases that targets the saliva of the mosquito rather than the pathogens carried by the insect.
The vaccine contains five synthetic peptides that originate from proteins found in the saliva of mosquitoes
AGS-v PLUS is owned by Imutex, a joint venture with PepTcell (the parent of ConserV Bioscience), in which hVIVO has a 49% shareholding.